888-78-8

Usage

Uses

Used in Pharmaceutical Research and Development:
4-amino-N-(2-methylphenyl)benzamide is used as a building block in the synthesis of various pharmaceuticals for its potential role in the development of new drugs. Its unique structure allows for the creation of diverse chemical entities with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, 4-amino-N-(2-methylphenyl)benzamide is utilized as an intermediate in the production of various agrochemicals, contributing to the development of effective pest control agents and other agricultural products.
Used in Medicinal Chemistry:
4-amino-N-(2-methylphenyl)benzamide serves as a research tool in medicinal chemistry, aiding scientists in understanding the compound's interactions with biological targets and its potential as a precursor for the synthesis of bioactive molecules.
Used in Biochemistry Research:
4-amino-N-(2-methylphenyl)benzamide is also employed in biochemistry research to explore its reactivity and binding properties with various biomolecules, which can provide insights into its potential applications in the development of diagnostic or therapeutic agents.

InChI:InChI=1/C14H14N2O/c1-10-4-2-3-5-13(10)16-14(17)11-6-8-12(15)9-7-11/h2-9H,15H2,1H3,(H,16,17)

Upstream product

• 122-04-3 4-nitro-benzoyl chloride 
• 95-53-4 o-toluidine 
• 150-13-0 4-amino-benzoic acid 
• 36855-81-9 4-nitro-N-o-tolyl-benzamide 

Relevant academic research and scientific papers

Rational design, synthesis and biological evaluation of dual PARP-1/2 and TNKS1/2 inhibitors for cancer therapy

Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors are the first and most successful drugs designed to exploit the concept of synthetic lethality (SL) between PARP-1 and BRCA1/2, which provides a novel strategy for tumor treatment. However, narrowed indications and resistance to PARP-1 inhibitors have hampered their further clinical application. Inducing “BRCAness” by targeting other targets, which will directly or indirectly disturb the homologous recombination (HR) repair pathway of double-strand DNA breaks (DSBs), is a promising strategy for expanding the clinical application of PARP-1 inhibitors and overcoming resistance to these inhibitors. Tankyrase1/2 (TNKS1/2) are involved in the nonhomologous end-joining (NHEJ) DNA repair pathway by regulating Wnt/β-catenin signaling. TNKS1/2 can also induce a “BRCAness” phenotype by regulating Wnt signaling, which increases the sensitivity of tumor cells with BRCA proficiency to PARP-1 inhibitors. These results suggest that cotargeting PARP1/2 and TNKS1/2 not only exerts a synergistic effect in the treatment of tumors but also provides a novel strategy for expanding the clinical application of PARP-1 inhibitors and overcoming resistance to PARP-1 inhibitors. Therefore, a series of dual PARP-1/2 and TNKS1/2 inhibitors were rationally designed, synthesized, and evaluated for their pharmacological properties. Among these candidates, compound I-9 showed excellent inhibitory activity as it inhibited PARP-1/2 and TNKS1/2 with IC50 values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM, respectively. I-9 exhibited favorable synergistic antitumor efficacy in both BRCA-mutant and BRCA-wild-type cancer lines. Moreover, I-9 exerted prominent dose-dependent antitumor activity in an HCT116 cell-derived xenograft model and was significantly more efficacious than olaparib and E7449. Overall, the present study indicated that I-9, a dual PARP-1/2 and TNKS1/2 inhibitor, is a novel and promising agent for cancer therapy.